| Autor: |
Marcinak CT; Department of Surgery, University of Wisconsin School of Medicine and Public Health University of Wisconsin-Madison, Madison, WI., Schwartz PB; Department of Surgery, University of Wisconsin School of Medicine and Public Health University of Wisconsin-Madison, Madison, WI., Basree MM; Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI., Hurst N; Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI., Bassetti M; Department of Human Oncology, University of Wisconsin Hospital and Clinics, Madison, WI., Kratz JD; University of Wisconsin-Madison, Madison, WI.; University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI.; Center for Human Genomics and Precision Medicine, University of Wisconsin, Madison, WI.; William S. Middleton Memorial Veterans Hospital, Madison, WI., Uboha NV; University of Wisconsin-Madison, Madison, WI.; University of Wisconsin Carbone Cancer Center, University of Wisconsin, Madison, WI. |
| Abstrakt: |
Oligometastatic state is believed to potentially represent a transitional stage between early, locoregional state disease and widely metastatic disease. Historically, locoregional approaches, particularly in advanced colorectal cancers, have demonstrated efficacy in select patients with limited burden of metastatic disease. Recent strides in systemic therapies, including biomarker-based treatments and immunotherapy, alongside innovations in surgical techniques and novel locoregional approaches such as stereotactic radiotherapy and ablation, have ushered in a new era of therapeutic possibilities across all oligometastatic GI cancers. Despite these advancements, there remains a significant gap in high-quality prospective evidence guiding patient selection and treatment decisions across various disease types. Ongoing clinical trials are anticipated to provide crucial insights into oligometastatic states, fostering the refinement of disease-specific oligometastatic state definitions and treatment algorithms. This article reviews existing data on the management of oligometastatic GI cancer, summarizes current state of knowledge for each disease state, and provides updates on ongoing studies in this space. |
